Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:GBNH

Greenbrook TMS (GBNH) Stock Price, News & Analysis

Greenbrook TMS logo

About Greenbrook TMS Stock (NASDAQ:GBNH)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$0.04
$0.10
50-Day Range
$0.05
$0.38
52-Week Range
$0.10
$1.82
Volume
787,000 shs
Average Volume
3.60 million shs
Market Capitalization
$1.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Greenbrook TMS Inc., together with its subsidiaries, controls and operates a network of outpatient mental health services centers in the United States. Its centers specialize in the provision of transcranial magnetic stimulation (TMS) therapy, an FDA-cleared non-invasive therapy for the treatment of major depressive disorder and other mental health disorders, as well as related psychiatric services. As of December 31, 2021, the company operated 94 wholly owned and 55 TMS centers in the commonwealth of Virginia and the States of Maryland, Delaware, North Carolina, Missouri, Illinois, Ohio, Texas, Connecticut, Florida, South Carolina, Michigan, Alaska, Oregon, California, Iowa, and Massachusetts. Greenbrook TMS Inc. was founded in 2011 and is headquartered in Toronto, Canada.

Remove Ads
Receive GBNH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Greenbrook TMS and its competitors with MarketBeat's FREE daily newsletter.

GBNH Stock News Headlines

Neuronetics reports preliminary Q4 revenue $22.1M, consensus $18.98M
Neuronetics Provides Business Update and Issues 2025 Guidance
Your Wealth is Under Attack
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Greenbrook TMS Inc (GBNHF)
Greenbrook TMS Strategic Acquisition and Restructuring by Neuronetics
Neuronetics Sees Q3 Revenue Rise Amid Strategic Acquisition
Neuronetics stockholders approve acquisition of Greenbrook TMS
Greenbrook TMS Shareholders Approve Neuronetics Acquisition
See More Headlines

GBNH Stock Analysis - Frequently Asked Questions

Greenbrook TMS Inc. (NASDAQ:GBNH) issued its quarterly earnings results on Monday, August, 14th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by $0.01. The company earned $18.35 million during the quarter, compared to analyst estimates of $19.15 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Greenbrook TMS investors own include RENN Fund (RCG), Aceragen (ACGN), Alimera Sciences (ALIM), Alpine Summit Energy Partners (ALPS), Angion Biomedica (ANGN), AirNet Technology (ANTE) and Aptorum Group (APM).

Company Calendar

Last Earnings
8/14/2023
Today
3/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
N/A
Current Symbol
NASDAQ:GBNH
Fax
N/A
Employees
492
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-61,730,000.00
Pretax Margin
-83.55%

Debt

Sales & Book Value

Annual Sales
$69.10 million
Price / Cash Flow
N/A
Book Value
($1.72) per share
Price / Book
-0.03

Miscellaneous

Free Float
31,959,000
Market Cap
$1.96 million
Optionable
Not Optionable
Beta
2.19
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:GBNH) was last updated on 3/13/2025 by MarketBeat.com Staff
From Our Partners